Navigation Links
High Speed Magnetic Stimulator (HSMS)

ProductsHigh Speed Magnetic Stimulator (HSMS)
Company Cadwell Laboratories, Inc.
Item High Speed Magnetic Stimulator (HSMS)
Features 
Description Magnetic stimulation is a non-invasive and painless method of stimulating the peripheral and central nervous system. Cadwell Laboratories manufactures two magnetic stimulation devices, the MES-10 and the High Speed Magnetic Stimulator (HSMS). The Hight Speed MES-10 magnetic stimulator is capable of stimulation rates up to 25 Hz at full power. Several coil configurations are available for each stimulator.

This device is approved for peripheral nerve and spinal cord stimulation. It is not approved for human cortical stimulation. The FDA requires an IDE (investigational device exemption) for studies involving human cortical stimulation with this device.
Info Cadwell Laboratories, Inc.
Customer Service: (800) 245-3001
Web site: http://www.cadwell.com

Related medicine products :

1. GR 20.22 Compact High Speed Refrigerated Floor-Standing Centrifuge
2. MR 23 Multi-Function Programmable High and Low Speed Refrigerated Centrifuge.
3. KR 22i High Speed Refrigerated Floor-Standing Centrifuge.
4. XK-95 High Speed Drill System
5. XK-PRO 100 High Speed Drill System
6. Hilan High Speed Drill System
7. Hilan XS High Speed Drill System
8. HeartSpeed HB Bi-plane Cardiac System
9. AngioSpeed H series
10. AngioSpeed V series
11. AngioSpeed VH
Other Medicine News:Health News:Frost & Sullivan Recognizes Strategic Healthcare Programs for Best Practices in Focused Innovation 2Health News:Frost & Sullivan Recognizes Strategic Healthcare Programs for Best Practices in Focused Innovation 3Health News:'That's My Hope' Audio Edition Released 2Health News:'That's My Hope' Audio Edition Released 3Health News:Saint Francis Medical Center Physician Services Implements MED3OOO RCM and ASP Services 2Health News:Saint Francis Medical Center Physician Services Implements MED3OOO RCM and ASP Services 3Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 2Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 3Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 4Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 5Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 6Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 7Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 8Health News:NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results 9Health News:AND Calls on DoD to Open All Military Units to Women, Grant Parental Leave to Service Members 2Health News:Cardiac Science to Present at the Roth 21st Annual OC Growth Stock Conference 2Health News:Cardiac Science to Present at the Roth 21st Annual OC Growth Stock Conference 3
Breaking Medicine Technology:Federal Judge Rejects GlaxoSmithKline's Claims of Privilege 2Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2Fresh Blood Boosts Survival in Trauma Patients 58799 1Fresh Blood Boosts Survival in Trauma Patients 58799 2Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 1Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 2Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 3Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 4Preventing Injuries In Firefighters Nationwide is New Research Focus for Top Sports Doc James Andrews M D and Athletes 26apos 3B Performance 58796 5Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 1Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 2Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 3Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 4Amicus Therapeutics Announces Preliminary Results of Phase 2 Study with Plicera 28TM 29 for Gaucher Disease 58793 5